Veraxa Biotech (NASDAQ:VRXA) Director Christoph Samuel Ziegler Buys 30,000 Shares of Stock

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Christoph Samuel Ziegler acquired 30,000 shares of the stock in a transaction dated Tuesday, October 20th. The shares were purchased at an average cost of $1.09 per share, with a total value of $32,700.00. Following the completion of the purchase, the director owned 37,932 shares of the company’s stock, valued at approximately $41,345.88. The trade was a 378.21% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Veraxa Biotech Price Performance

Shares of NASDAQ VRXA traded up $0.05 during trading hours on Wednesday, hitting $1.06. The company’s stock had a trading volume of 197,872 shares, compared to its average volume of 463,167. Veraxa Biotech Holding AG has a 12 month low of $0.99 and a 12 month high of $27.36.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Veraxa Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 31st.

About Veraxa Biotech

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.